| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC3160 |
| Trial ID | NCT05517642 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran;Ad5-nCoV-IH |
| Co-treatment | Ad5-nCoV-IH |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;NULL |
| Phase | Phase3 |
| Recruitment status | Completed |
| Title | Immunogenicity, Efficacy and Safety of Inhaled (IH) Viral Vectored Vaccine (Convidecia, CanSino) as Second Booster Dose Against Emerging Variants of Concern (VOC) of SARS-CoV-2 to Prevent Breakthrough Infections. A Randomized Observer-blind Controlled Trial. |
| Year | 2022 |
| Country | Malaysia |
| Company sponsor | CanSino Biologics Inc. |
| Other ID(s) | CT 2022-01 |
| Vector information | |||
|
|||
| Cohort1: Ad5-nCoV-IH | |||||||
|
|||||||
| Cohort2: BNT162b2 | |||||||
|
|||||||